Lv4
452 积分 2025-06-10 加入
Structural and Functional Diversity in the FGf Receptor Multigene Family
1个月前
已完结
Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma
1个月前
已完结
FGFR2 Inhibition in Cholangiocarcinoma
1个月前
已完结
FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions
1个月前
已完结
Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach
1个月前
已完结
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity acrossFGFR2Alterations and Resistance Mutations
1个月前
已完结
Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer
1个月前
已完结
Futibatinib: First Approval
1个月前
已完结
The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide
1个月前
已完结
Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2
1个月前
已完结
皖公网安备34019202002308
